▎WuXiEdited by Kant Content Team

Today, Boehringer Ingelheim and Ipsen have each reached research and licensing cooperation agreements exceeding 1 billion US dollars, respectively.Layout includes chronic liver disease areas such as metabolic function-related steatohepatitis (MASH) and small molecule therapies targeting RNA.. Two promising companies dedicated to developing potential "first-in-class" and "best-in-class" therapies have also successfully completed early-stage financing.

Prevent or Reverse Liver Disease: Boehringer Ingelheim Secures Over $1 Billion Collaboration

Ochre Bio's proprietary discovery platform combines machine learning and large-scale human data, including advanced imaging and DNA omics data, as well as RNA chemistry and human organoid models. It facilitates the discovery, testing, and validation of innovative regenerative targets for treating chronic liver diseases. This collaboration aims toDevelop innovative therapies with the potential to enhance the liver's self-repair capabilities, preventing or reversing disease progression.

Ochre Bio to Receive $35 Million in Upfront and Near-Term Milestone Payments, Plus Potential Subsequent Development, Regulatory, and Commercialization Milestone Payments Exceeding $1 Billion.

Ipsen Partners to Develop RNA-Targeted Small Molecule Therapies in $1.8 Billion Deal

Under the agreement, Ipsen has the right to opt for the global development rights of two candidate therapies generated from the collaboration. After the candidate therapies are validated, Ipsen will take full responsibility for their subsequent development and commercialization. Skyhawk is eligible to receive up to $1.8 billion in development, regulatory, and commercial milestone payments.

Developing Potential "First-in-Class" Therapies, Rubedo Life Sciences Closes $40 Million Series A Financing

The company's ALEMBIC drug discovery platform aims to selectively target different senescent cells and design potential "first-in-class" small molecule therapies. Senescent cells play a crucial role in pulmonary, dermatological, oncological diseases, as well as neurodegenerative and fibrotic conditions. The company'sThe flagship therapy RLS-1496, currently under research, aims to target senescent cells in the skin to treat atopic dermatitis and psoriasis. This small-molecule therapy is about to enter Phase 1 clinical trials.

In TGCT patients, the overexpression of CSF-1 suppresses T cell-mediated anti-cancer immune responses.Emactuzumab promotes T-cell infiltration and anti-cancer immune response by inhibiting the CSF-1 receptor-mediated signaling pathway. Previous clinical trial data showed that emactuzumab achieved an objective response rate (ORR) of 71%., which can quickly shrink tumors and has long-lasting efficacy, significantly improving patients' functional indicators. These studies also show that emactuzumab has good safety and tolerability. The press release stated that this next-generation antibody therapy has the potential to become a "best-in-class" TGCT treatment.

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long-press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.